Latest News
What fundamentals are crucial when assesing a startup? – Investment Manager Natasha Rawlings
Natasha Rawlings, the Uniseed Investment Manager for Sydney, sat down with Sidney Macdessi of CRIISP Media to discuss what researchers and founders can do to make the most of an initial conversation with an investor, and how talking to potential customers is your...
2021 Prize for New Innovators – Associate Professor Michael Bowen
Co-founder of Uniseed investee Kinoxis, Associate Professor Michael Bowen has been awarded the Prime Minister's Prize for New Innovators for his discovery and development of KNX100, a novel molecule that is being commercialised to treat addiction and...
Liquid metal proven to be cheap and efficient CO2 converter
Uniseed investee LM+, as part of a global collaboration led by researchers from UNSW, has shown how liquid gallium can be used to help achieve the important goal of net zero carbon emissions. Engineers from UNSW have helped to discover a cheap new way to...
First-in-Class, Broad-Spectrum Nasal Spray to Prevent COVID-19 and Other Common Respiratory Illnesses Set to Begin Phase 2 Trials
28 September 2021 – ENA Respiratory, a biotechnology company developing a first-in-class nasal spray for the prevention of COVID-19 and other respiratory viral infections, announced today that it has engaged research partners PPD,...
CO2 conversion company LM Plus secures $600,000 seed funding led by Uniseed
2 August 2021: Australian technology company LM Plus Pty Ltd has closed a $600,000 Seed financing round to fund process optimisation and proof of concept of a novel liquid metal technology that converts CO2 into saleable carbon flakes and oxygen The...
Uniseed Investee ENA Respiratory seeks participants for promising Australian COVID-19 preventative nasal spray – Sydney Phase I clinical trial
First-in-class, fast-acting nasal spray designed to boost innate immunity against respiratory viruses including COVID-19, influenza and the common cold, seeks participants for first in-human safety trial in Sydney
Uniseed Completes 60th Start-Up Investment from Partner Research Organisations
Last week Uniseed announced its investment in Currus Biologics, a Melbourne-based cancer biotech start-up working to improve the success of CAR-T cell therapies against solid tumours, representing the 60th investment completed by the Uniseed fund since it was formed in late 2000.
$10m invested into start-up developing new treatments targeting the use of CAR-T cell therapies against solid tumours
Currus Biologics, a Melbourne-based cancer biotech start-up, has completed an AU$10 million investment round to improve the success of CAR-T cell therapies against solid tumours such as breast, ovarian and pancreatic cancers.
Uniseed Investee ENA Respiratory Advances COVID-19 Preventative Therapy through AU$32 Million Fund Raise
ENA Respiratory Advances COVID-19 Preventative Therapy through AU$32 Million Fund Raise
– Round jointly led by Brandon Capital and Minderoo Foundation with co-investment from Uniseed will support the clinical development of INNA-051
– Company appoints President and Chief Scientific Officer of the COPD Foundation and respiratory therapy expert Ruth Tal-Singer, Ph.D. to Board of Directors
Uniseed seeking Investment Intern – Position Filled
Uniseed is seeking an Investment Intern to join our team … a tremendous opportunity for a recent graduate to gain exposure to all aspects of the operation of a venture capital fund.